ChemoCentryx Inc (ChemoCentryx) is a bio pharmaceutical company that discovers, develops and commercializes orally-administered therapeutics for the treatment of cancer, autoimmune diseases and inflammatory disorders. The company's pipeline product includes Avacopan, CCX559,CCX587 and CCX507. Its Avacopan a lead candidate is an orally-administered complement inhibitor of the complement C5a receptor (C5aR), for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. ChemoCentryx also provide preclinical research for evaluating the effect of combination therapy with chemokine receptor and check point inhibitors. ChemoCentryx is headquartered in Mountain View, California, the US.

Headquarters United States of America

Address 835 Industrial Road, Suite 600, San Carlos, California, 94070


Telephone 1 650 2102900

No of Employees 178

Industry Pharmaceuticals and Healthcare

Revenue (2021) $32.2M

   

   

Access premium data and analytics for ChemoCentryx Inc

40+

Clinical Trials

Determine ChemoCentryx Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

30+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for ChemoCentryx Inc’s relevant decision makers and contact details.

30+

Pipeline Drugs

Identify which of ChemoCentryx Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

18+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

5

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Marketed Drugs

Understand ChemoCentryx Inc’s commercialized product portfolio to stay one step ahead of the market.

40+

Install Base

Install Base provides a holistic and a granular view of the IT product/service deployments from leading vendors. Explore IT infrastructure categories, solution and product/service areas deployed by a prospect.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on ChemoCentryx Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Services Brands
Pipeline Clinical Development Tavneos
Tavneos (Avacopan)
CCX559 / PD-1 / PD-L1 (Immuno-Oncology)
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Others In August, the company announced Tavneos (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA).
2022 Contracts/Agreements In August, the company agreed to be acquired by Amgen Inc for US$3.7 billion.
2022 Regulatory Approval In January, the company approved within the European Union in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA).
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters ChemoCentryx Inc Assertio Therapeutics Inc Enzo Biochem Inc MediciNova Inc Galectin Therapeutics Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City San Carlos Lake Forest Farmingdale La Jolla Norcross
State/Province California Illinois New York California Georgia
No. of Employees 178 - 465 11 9
Entity Type Private Private Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Executives
Name Position Board Since Age
Thomas J. Schall President; Chief Executive Officer; Chairman Executive Board 2012 62
Rita Jain Senior Vice President; Chief Medical Officer; Director Executive Board 2019 59
Tausif Butt Executive Vice President; Chief Operating Officer Senior Management 2021 56
Kari E. Leetch Senior Vice President - Human Resources Senior Management - -
Markus J. Cappel Chief Business Officer and Treasurer Senior Management 2007 61
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company Analytics

Contact the team or request a demo to find out how our data can drive your business forward

Why are you leaving?